Rituximab (RTX; anti-CD20 monoclonal antibody) is a treatment option in children with refractory immune thrombocytopenia (ITP), autoimmune haemolytic anaemia (AHA) and Evans syndrome (ES). Prevalence and clinical course of RTX-induced hypogammaglobulinemia in these patients are poorly known.

Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia

Giordano, Paola;Lassandro, Giuseppe;ANGARANO, ROSA;
2019

Abstract

Rituximab (RTX; anti-CD20 monoclonal antibody) is a treatment option in children with refractory immune thrombocytopenia (ITP), autoimmune haemolytic anaemia (AHA) and Evans syndrome (ES). Prevalence and clinical course of RTX-induced hypogammaglobulinemia in these patients are poorly known.
File in questo prodotto:
File Dimensione Formato  
ottaviano2019.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 362.31 kB
Formato Adobe PDF
362.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11586/241688
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 20
social impact